When you drink alcohol, your liver breaks it down in two steps. First, an enzyme converts alcohol into acetaldehyde — a compound similar to formaldehyde that's toxic and damages DNA. Normally, a second enzyme, aldehyde dehydrogenase 2 (ALDH2), quickly clears that acetaldehyde before it accumulates. In people with a specific ALDH2 gene variant (called ALDH2*2 or rs671), that second enzyme works far less efficiently, so acetaldehyde builds up in the bloodstream — causing the facial flushing, rapid heartbeat, and nausea that give the trait its common nickname.
Roughly a Third of East Asians Carry It
Approximately 36% of Japanese, Chinese, and Korean populations show the characteristic flushing response, and the underlying ALDH2*2 variant is one of the most common functional genetic polymorphisms in humans. It's largely absent outside East Asian ancestry, making it one of the more population-specific variants in consumer genomics — most testing companies and even some doctors outside East Asia simply don't think to check for it.
The Part Most People Miss: This Is a Cancer Risk Marker
The flushing itself is uncomfortable but not dangerous. What matters clinically is what it signals: acetaldehyde is classified as a Group 1 carcinogen, and ALDH2-deficient individuals who continue drinking despite the flush accumulate significantly more of it in their tissues per drink than people with normal ALDH2 function. Research has linked ALDH2 deficiency to a several-fold increase in esophageal cancer risk among people who drink alcohol regularly, with some estimates putting the increased risk at four to eight times higher compared to non-deficient drinkers who consume similar amounts. The risk is compounded further in heterozygous carriers (one copy of the variant) specifically, because — somewhat counterintuitively — full homozygous deficiency tends to cause such severe discomfort that most people avoid drinking altogether, while heterozygotes experience milder symptoms and are more likely to keep drinking through them.
| Genotype | Typical experience | Cancer risk relevance |
|---|---|---|
| No ALDH2 deficiency | No flush; normal acetaldehyde clearance | Baseline risk |
| Heterozygous | Moderate flush; often continues drinking | Elevated esophageal cancer risk with regular drinking |
| Homozygous | Severe flush/nausea; drinking often avoided entirely | Highest per-drink risk, but often self-limiting due to symptom severity |
Facial flushing after drinking isn't just an embarrassing quirk — it's a visible biomarker for a genetic trait tied to substantially elevated esophageal cancer risk with continued alcohol use. Public health researchers have specifically recommended that clinicians ask East Asian patients about flushing history as a quick, free way to identify this risk without needing a genetic test at all — though a genetic test confirms it definitively and catches cases people might not have noticed themselves.
What To Do With This Information
If you experience alcohol flushing, or know your genome shows ALDH2 deficiency, the most protective step is straightforward: reduce or eliminate regular alcohol consumption. This isn't about willpower or tolerance-building — the biological mechanism means the risk doesn't diminish with practice the way people sometimes assume tolerance works for other symptoms. If you have a history of regular drinking despite flushing, discussing endoscopic esophageal cancer screening with your doctor is a reasonable conversation, particularly if you also smoke, which compounds the risk further.
Know Your Alcohol Metabolism Genetics Before It Matters
Dante Labs' whole genome sequencing captures ALDH2 status alongside other pharmacogenomic and health-relevant variants in one test. Use code GENOME for 10% off.
Get Sequenced with Dante Labs → 10% off with code GENOMEFor more on how genetics shapes your relationship with food and drink, see our nutrigenomics guide. And for the bigger picture on hereditary cancer risk, our genome testing and cancer risk guide covers other genes worth knowing.